@AponiaAnalytics AponiaAnalytics
Numerate biotech catalyst analyst dissecting trial data, dilution, and insider flow
Publishes original, mechanism-aware analysis of biotech/phar
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY. · Analyst brief as of 2026-06-22.
Across their last 20 scored bets: 45% hit rate, +0.88% mean alpha, trader score +0.89. Their last-14d mentions, direction-adjusted, have moved +2.1% since posting (mean over 52 mentions with price data).
AponiaAnalytics is mostly surfacing biotech filing and clinical/regulatory updates, not making explicit directional calls or position disclosures. The distinctive read is concentrated surveillance of QURE and NKTR insider-sale Form 4s, offset by selective positive clinical/regulatory data on NTLA, LLY, INCY, MIRM, and QURE. There is no explicit late-week trade flip; the window ends with more QURE/NKTR sale coverage plus QURE AMT-260 data.
No explicit CALL_DIRECTIONAL trades, adds, trims, exits, or position flips appeared in the input. Coverage is concentrated in QURE and NKTR filing flow, especially insider-sale notices, while clinical/regulatory posts are selectively constructive for NTLA, LLY, INCY, and QURE. Pump-risk or concentration risk is highest in QURE because it represents 13 of 42 signals and dominates the most detailed narrative.
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-07-01 | SRPT | @AponiaAnalytics | +0.00 | Reports Sarepta granted 151,305 inducement RSUs to 30 Q2 hires. | · | tweet ↗ |
| 2026-07-01 | ABVX | @AponiaAnalytics | -0.05 | Abivax expanded shelf to include debt securities, broadening financing flexibility. | +9.1% | tweet ↗ |
| 2026-07-01 | QURE | @AponiaAnalytics | -0.10 | CMO plans to sell 30,000 shares worth about $1.39M under 10b5-1 plan. | -7.4% | tweet ↗ |
| 2026-07-01 | QURE | @AponiaAnalytics | -0.10 | Director plans to sell 21,167 shares worth about $983K under 10b5-1 plan. | -7.4% | tweet ↗ |
| 2026-07-01 | SRPT | @AponiaAnalytics | +0.15 | FDA accepted sNDAs with Feb. 28, 2027 PDUFA but trial missed primary endpoint. | · | tweet ↗ |
| 2026-07-01 | NKTR | @AponiaAnalytics | -0.10 | Officer plans to sell 5,681 shares worth about $371K under 10b5-1 plan. | +10.3% | tweet ↗ |
| 2026-07-01 | ABVX | @AponiaAnalytics | -0.35 | Abivax launched about $600M ADS offering with dilution risk. | +9.1% | tweet ↗ |
| 2026-07-01 | QURE | @AponiaAnalytics | +0.00 | CMO sold 1,434 shares solely for tax withholding after RSU vesting. | -7.4% | tweet ↗ |
| 2026-07-01 | ABVX | @AponiaAnalytics | -0.25 | Abivax $600M ADS prospectus funds launch/R&D but brings dilution. | +9.1% | tweet ↗ |
| 2026-07-01 | OSCR | @AponiaAnalytics | -0.05 | CEO sold about 1.24M shares under prearranged 10b5-1 plan for taxes. | +0.9% | tweet ↗ |
| 2026-07-01 | SGMO | @AponiaAnalytics | -0.25 | Sangamo dismissed EY after Chapter 11 filing and has no replacement auditor yet. | — | tweet ↗ |
| 2026-07-01 | ABVX | @AponiaAnalytics | -0.10 | Abivax upsized ADS raise to $800M, runway to Q2 2029, dilution about 8%. | +9.1% | tweet ↗ |
| 2026-07-01 | RGNX | @AponiaAnalytics | +0.00 | REGENXBIO amended Schedule TO only to add employee reminder, no term changes. | · | tweet ↗ |
| 2026-07-01 | ABVX | @AponiaAnalytics | +0.00 | Euronext Paris trading resumed after Abivax ADS pricing/allocation completion. | +9.1% | tweet ↗ |
| 2026-07-01 | ABVX | @AponiaAnalytics | -0.10 | Abivax upsized ADS offering to $800M at 2.39% VWAP premium, dilution about 8%. | +9.1% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.